Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 17, Issue -, Pages S441-S448Publisher
WILEY
DOI: 10.1046/j.1440-1746.17.s4.7.x
Keywords
aflatoxin; biomarkers; carcinogen adducts; hepatitis B virus; hepatocellular carcinoma; liver; molecular epidemiology
Categories
Funding
- NIEHS NIH HHS [ES06052] Funding Source: Medline
Ask authors/readers for more resources
Aflatoxins and hepatitis B virus (HBV) are major risk factors for hepatocellular carcinoma (HCC) in South-east Asia and Africa, parts of the world where this cancer is most prevalent. Exposure to both factors is endemic, occurring from early in life. There is evidence from both epidemiological studies and animal models that the two factors can act synergistically to increase the risk of HCC, but the underlying cellular and molecular mechanisms of interaction are as yet undefined. One possiblity suggested by studies in HBV transgenic mice is that chronic liver injury alters the expression of carcinogen metabolizing enzymes, thus modulating the level of binding of aflatoxin to DNA. Primary prevention of HCC in high incidence areas of the world should primarily be focused on provision of the safe, effective vaccine against HBV. However, measures to reduce the high levels of aflatoxin exposure, where chronic HBV infection is currently epidemic, would also significantly contribute to reducing HCC incidence. In Guinea-Conakry, West Africa, surveys of HBV infection and aflatoxin exposure have established baseline data for the implementation of a community-based intervention study. This study will evaluate the effectiveness of improving the post-harvest processing and storage of the groundnut crop, a major source of aflatoxins, using aflatoxin-albumin adducts as the outcome measurement. (C) 2002 Blackwell Publishing Asia Pty Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available